This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Oncology  • Oncology, Other  • Dermatology  • Dermatologic Disorders  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Gastroenterology  • Gastrointestinal Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Maxime Battistella, MD; Guillemette Frémont, MD; Marie-Dominique Vignon-Pennamen, MD; Jean-Marc Gornet, MD; Louis Dubertret, MD, PhD; Manuelle Viguier, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Imatinib has become a main chemotherapeutic agent, especially for metastatic gastrointestinal stromal tumors (GISTs) and chronic myeloid leukemia. To our knowledge, we report herein the first case of hand-foot syndrome induced by this drug.

Report of a Case

A 49-year-old man with no known medical history was diagnosed as having metastatic GIST in July 2006. A computed tomographic scan revealed large bilobar hepatic nodules, and upper digestive endoscopy revealed a 3-cm ulcerated submucosal lesion of the antrum having a gross aspect consistent with GIST. Biopsy confirmed the diagnosis of malignant GIST with a high expression of CD117.

Treatment with imatinib was begun at 400 mg/d. No other medication was prescribed. Three weeks after treatment initiation, the patient developed moderate cheilitis, tongue pain, and acral eruption. He experienced painful, edematous palmoplantar erythema, which spread over the . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?